Trial Outcomes & Findings for Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease (NCT NCT05843916)

Last Updated: 2026-02-18

Results Overview

The primary objective of the study is to evaluate the equivalence in efficacy between AGA BETA BS and Fabrazyme® after 6 months of treatment in participants with Fabry disease previously stabilized with Fabrazyme, by measuring disease biomarker. Endpoint: Mean serum Lyso-Gb3 marker ratio after 26 weeks of treatment, defined as serum level of the marker Lyso-Gb3 after 26 weeks (6 months) divided by serum level of the marker Lyso-Gb3 at baseline.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

20 participants

Primary outcome timeframe

Baseline (after 5 week lead-in period on Fabrazyme®) and 26 weeks (after the switch to AGA BETA BS)

Results posted on

2026-02-18

Participant Flow

Participant milestones

Participant milestones
Measure	Fabrazyme Then AGA BETA BS The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
Lead in (Fabrazyme) STARTED	20
Lead in (Fabrazyme) COMPLETED	19
Lead in (Fabrazyme) NOT COMPLETED	1
Treatment Period (AGA BETA BS) STARTED	19
Treatment Period (AGA BETA BS) COMPLETED	18
Treatment Period (AGA BETA BS) NOT COMPLETED	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Fabrazyme Then AGA BETA BS The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
Lead in (Fabrazyme) Withdrawal by Subject	1
Treatment Period (AGA BETA BS) Pregnancy	1

Baseline Characteristics

Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Fabrazyme Then AGA BETA BS n=20 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
Ethnicity (NIH/OMB) Not Hispanic or Latino	0 Participants n=4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=4 Participants
Age, Continuous	35.6 years STANDARD_DEVIATION 12.6 • n=4 Participants
Sex: Female, Male Female	15 Participants n=4 Participants
Sex: Female, Male Male	5 Participants n=4 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	20 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	0 Participants n=4 Participants
Race (NIH/OMB) White	20 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=4 Participants
Region of Enrollment Argentina	20 participants n=4 Participants
Height	162.2 Centimeters STANDARD_DEVIATION 7.7 • n=4 Participants
Weight	69.9 Kilograms STANDARD_DEVIATION 15.3 • n=4 Participants
BMI	26.4 Kg/m2 STANDARD_DEVIATION 6.2 • n=4 Participants
Fabry disease Phenotype Classic Male	5 Participants n=4 Participants
Fabry disease Phenotype Classic Female	15 Participants n=4 Participants
Fabry disease Phenotype Late Onset Male	0 Participants n=4 Participants
Fabry disease Phenotype Late Onset Female	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®) and 26 weeks (after the switch to AGA BETA BS)

Population: Differences are explained by the availability of samples collected within the correct protocol-defined window and the withdrawal of one subject before the start of the treatment period.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=20 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) n=17 Participants Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Change From Baseline in Lyso Gb3 Serum Levels Mean baseline Lyso-Gb3	4.99 Nmol/L Standard Deviation 3.10	5.12 Nmol/L Standard Deviation 3.15
Change From Baseline in Lyso Gb3 Serum Levels Mean 26 weeks Lyso-Gb3	4.95 Nmol/L Standard Deviation 3.31	5.14 Nmol/L Standard Deviation 3.45

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®) and 54 weeks (after the switch to AGA BETA BS)

Population: Differences are explained by the availability of samples collected within the correct visit window, the withdrawal of one subject before the start of the treatment period, and the discontinuation of one subject due to pregnancy before the Week 54 study visit.

To evaluate the difference in efficacy between AGA BETA BS and Fabrazyme® after 1 year (54 weeks) of treatment in participants with Fabry disease previously stabilized with Fabrazyme®, by measuring disease biomarker. Endpoint: Mean serum Lyso-Gb3 marker ratio after 54 weeks of treatment, defined as serum level of the marker Lyso-Gb3 after 54 weeks (12 months) divided by serum level of the marker Lyso-Gb3 at baseline.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=20 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) n=17 Participants Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Change From Baseline in Lyso-Gb3 Serum Levels Mean baseline Lyso-Gb3	4.99 Nmol/L Standard Deviation 3.102	5.12 Nmol/L Standard Deviation 3.15
Change From Baseline in Lyso-Gb3 Serum Levels Mean 54 weeks Lyso-Gb3	4.69 Nmol/L Standard Deviation 3.51	4.71 Nmol/L Standard Deviation 3.61

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

To compare the pain severity before and after the treatment with AGA BETA BS in participants with Fabry disease previously stabilized with Fabrazyme®, as measured by the Brief Pain Inventory-short form (BPI). The Brief Pain Inventory (BPI) is a validated patient-reported outcome instrument assessing pain severity and pain-related interference with daily activities. Pain severity is assessed using four items rated on a 0-10 numeric rating scale (0 = no pain; 10 = pain as bad as imaginable), with the score calculated as the mean of items (range 0-10; higher scores indicate worse pain). Pain interference is assessed using seven items rated on a 0-10 numeric rating scale (0 = does not interfere; 10 = completely interferes), with the score calculated as the mean of items (range 0-10; higher scores indicate worse outcome). Endpoint: Change from baseline in pain severity as assessed by BPI-short form pain severity items scores after 26 and 54 weeks of treatment.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Change From Baseline in Pain Severity as Assessed by Brief Pain Inventory-short Form Pain Severity Items Scores Baseline	1.88 Scores on a scale Standard Deviation 2.02	—
Change From Baseline in Pain Severity as Assessed by Brief Pain Inventory-short Form Pain Severity Items Scores 26 weeks	1.46 Scores on a scale Standard Deviation 2.04	—
Change From Baseline in Pain Severity as Assessed by Brief Pain Inventory-short Form Pain Severity Items Scores 54 weeks	1.18 Scores on a scale Standard Deviation 2.24	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N reflects the discontinuation of one subject due to pregnancy before week 54 visit and the availability of determinations that were either missing at specific visits or collected outside the correct protocol-defined window.

To compare the impact of pain on daily functions before and after the treatment with AGA BETA BS in participants with Fabry disease previously stabilized with Fabrazyme®, as measured by the BPI (Brief Pain Inventory)-short form. The Brief Pain Inventory (BPI) is a validated patient-reported outcome instrument assessing pain severity and pain-related interference with daily activities. Pain severity is assessed using four items rated on a 0-10 numeric rating scale (0 = no pain; 10 = pain as bad as imaginable), with the score calculated as the mean of items (range 0-10; higher scores indicate worse pain). Pain interference is assessed using seven items rated on a 0-10 numeric rating scale (0 = does not interfere; 10 = completely interferes), with the score calculated as the mean of items (range 0-10; higher scores indicate worse outcome). Endpoint: Change from baseline in pain severity as assessed by BPI-short form pain severity items scores after 26 and 54 weeks of treatment.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Change From Baseline in Pain Interference as Assessed by BPI-short Form Pain Interference Items Scores Baseline	2.56 Scores on a scale Standard Deviation 3.03	—
Change From Baseline in Pain Interference as Assessed by BPI-short Form Pain Interference Items Scores 26 weeks	1.64 Scores on a scale Standard Deviation 2.36	—
Change From Baseline in Pain Interference as Assessed by BPI-short Form Pain Interference Items Scores 54 weeks	2.25 Scores on a scale Standard Deviation 2.8	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

To compare the participants' perception of their own health before and after the treatment with AGA BETA BS in participants with Fabry disease previously stabilized with Fabrazyme®, as measured by the Short Form-36 Health Survey (SF-36). The Short Form-36 Health Survey (SF-36) is a validated patient-reported outcome instrument consisting of 36 questions designed to assess health-related quality of life. The questionnaire generates scores across eight domains (physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems, and emotional well being), each scored on a 0-100 scale. Domain scores are calculated according to standard scoring algorithms, with higher scores indicating better health status and quality of life. Endpoint: Change from baseline in SF-36 scores after 26 and 54 weeks of treatment.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Change From Baseline in SF-36 Health Survey Scores Physical Functioning Score - Mean Baseline	79.5 Scores on a scale Standard Deviation 21.01	—
Change From Baseline in SF-36 Health Survey Scores Physical Functioning Score - Mean 26 weeks	78.7 Scores on a scale Standard Deviation 24.99	—
Change From Baseline in SF-36 Health Survey Scores Physical Functioning Score - Mean 54 weeks	76.7 Scores on a scale Standard Deviation 24.43	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to physical health- Mean Baseline	71.1 Scores on a scale Standard Deviation 41.05	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to physical health-Mean 26 weeks	73.7 Scores on a scale Standard Deviation 38.62	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to physical health- Mean 54 weeks	76.4 Scores on a scale Standard Deviation 42.42	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to emotional problems-Mean Baseline	50.88 Scores on a scale Standard Deviation 44.95	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to emotional problems- Mean 26 weeks	70.18 Scores on a scale Standard Deviation 45.67	—
Change From Baseline in SF-36 Health Survey Scores Role limitations due to emotional problems- Mean 54 weeks	62.96 Scores on a scale Standard Deviation 46.99	—
Change From Baseline in SF-36 Health Survey Scores Energy/fatigue- Mean Baseline	51.10 Scores on a scale Standard Deviation 21.38	—
Change From Baseline in SF-36 Health Survey Scores Energy/fatigue- Mean 26 weeks	60.30 Scores on a scale Standard Deviation 22.27	—
Change From Baseline in SF-36 Health Survey Scores Energy/fatigue - Mean 54 weeks	55 Scores on a scale Standard Deviation 16.36	—
Change From Baseline in SF-36 Health Survey Scores Emotional well-being - Mean Baseline	68.6 Scores on a scale Standard Deviation 20.54	—
Change From Baseline in SF-36 Health Survey Scores Emotional well-being- Mean 26 weeks	71.2 Scores on a scale Standard Deviation 17.21	—
Change From Baseline in SF-36 Health Survey Scores Emotional well-being- Mean 54 weeks	64.7 Scores on a scale Standard Deviation 15.84	—
Change From Baseline in SF-36 Health Survey Scores Social functioning- Mean Baseline	79.61 Scores on a scale Standard Deviation 19.92	—
Change From Baseline in SF-36 Health Survey Scores Social functioning- Mean 26 weeks	77.24 Scores on a scale Standard Deviation 27.22	—
Change From Baseline in SF-36 Health Survey Scores Social functioning- Mean 54 weeks	79.17 Scores on a scale Standard Deviation 20.29	—
Change From Baseline in SF-36 Health Survey Scores Pain- Mean Baseline	69.61 Scores on a scale Standard Deviation 27.03	—
Change From Baseline in SF-36 Health Survey Scores Pain- Mean 26 weeks	74.21 Scores on a scale Standard Deviation 25.90	—
Change From Baseline in SF-36 Health Survey Scores Pain- Mean 54 weeks	84.17 Scores on a scale Standard Deviation 23.87	—
Change From Baseline in SF-36 Health Survey Scores General Health-Mean Baseline	60.30 Scores on a scale Standard Deviation 22.28	—
Change From Baseline in SF-36 Health Survey Scores General Health-Mean 26 weeks	62.40 Scores on a scale Standard Deviation 20.77	—
Change From Baseline in SF-36 Health Survey Scores General Health- Mean 54 weeks	57.80 Scores on a scale Standard Deviation 24.27	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 14 weeks, 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The differences in N across visits reflect the discontinuation of one subject due to pregnancy before week 54 visit and the availability of laboratory determinations at each scheduled visit.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Blood Urea Nitrogen (BUN) Levels at Specified Timepoints Mean Baseline Blood Urea Nitrogen	5.03 mmol/L Standard Deviation 2.19	—
Mean Blood Urea Nitrogen (BUN) Levels at Specified Timepoints Mean 14 weeks Blood Urea Nitrogen	4.70 mmol/L Standard Deviation 1.76	—
Mean Blood Urea Nitrogen (BUN) Levels at Specified Timepoints Mean 26 weeks Blood Urea Nitrogen	4.34 mmol/L Standard Deviation 1.40	—
Mean Blood Urea Nitrogen (BUN) Levels at Specified Timepoints Mean 54 weeks Blood Urea Nitrogen	4.78 mmol/L Standard Deviation 1.82	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Estimated Glomerular Filtration Rate (eGFR) at Specified Timepoints Mean Baseline eGFR	106.05 ml/min/1.73m2 Standard Deviation 25.32	—
Mean Estimated Glomerular Filtration Rate (eGFR) at Specified Timepoints Mean 26 weeks eGFR	107.99 ml/min/1.73m2 Standard Deviation 27.02	—
Mean Estimated Glomerular Filtration Rate (eGFR) at Specified Timepoints Mean 54 weeks eGFR	100.47 ml/min/1.73m2 Standard Deviation 26.54	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The differences in N across visits reflect the discontinuation of one subject due to pregnancy and the availability of laboratory determinations at each scheduled visit.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Urine Albumin-to-Creatinine Ratio at Specified Timepoints Mean Baseline Urine Albumin/Creatinine ratio	9.26 g/mol Standard Deviation 13.95	—
Mean Urine Albumin-to-Creatinine Ratio at Specified Timepoints Mean 26 weeks Urine Albumin/Creatinine ratio	9.14 g/mol Standard Deviation 12.16	—
Mean Urine Albumin-to-Creatinine Ratio at Specified Timepoints Mean 54 weeks Urine Albumin/Creatinine ratio	9.8 g/mol Standard Deviation 20.52	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 14 weeks, 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The differences in N across visits reflect the discontinuation of one subject due to pregnancy and the availability of laboratory determinations at each scheduled visit.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Sodium	141.10 mmol/L Standard Deviation 3.16	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Sodium	140.30 mmol/L Standard Deviation 2.91	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Sodium	140.40 mmol/L Standard Deviation 2.89	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Sodium	140.80 mmol/L Standard Deviation 4.71	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Potassium	4.22 mmol/L Standard Deviation 0.41	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Potassium	4.36 mmol/L Standard Deviation 0.45	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Potassium	4.31 mmol/L Standard Deviation 0.37	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Potassium	4.25 mmol/L Standard Deviation 0.58	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Magnesium	0.84 mmol/L Standard Deviation 0.13	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Magnesium	0.83 mmol/L Standard Deviation 0.11	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Magnesium	0.83 mmol/L Standard Deviation 0.09	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Magnesium	0.85 mmol/L Standard Deviation 0.12	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Calcium	2.43 mmol/L Standard Deviation 0.14	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Calcium	2.37 mmol/L Standard Deviation 0.12	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Calcium	2.36 mmol/L Standard Deviation 0.14	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Calcium	2.40 mmol/L Standard Deviation 0.13	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Chloride	104.28 mmol/L Standard Deviation 4.26	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Chloride	104.49 mmol/L Standard Deviation 4.82	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Chloride	104.72 mmol/L Standard Deviation 5.24	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Bicarbonate	24.18 mmol/L Standard Deviation 2.84	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Bicarbonate	24.47 mmol/L Standard Deviation 2.33	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Bicarbonate	24.25 mmol/L Standard Deviation 2.44	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Bicarbonate	23.78 mmol/L Standard Deviation 2.50	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean Baseline Phosphate	1.12 mmol/L Standard Deviation 0.40	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Phosphate	1.11 mmol/L Standard Deviation 0.28	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 26 weeks Phosphate	1.21 mmol/L Standard Deviation 0.25	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 54 weeks Phosphate	1.28 mmol/L Standard Deviation 0.22	—
Mean Electrolyte and Phosphate Levels at Specified Timepoints Mean 14 weeks Chloride	103.71 mmol/L Standard Deviation 3.51	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

Evaluation of Heart Rate based on the analysis of electrocardiogram exams performed at baseline, 26 weeks and 54 weeks.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Heart Rate From Electrocardiogram Assessments at Specified Timepoints Baseline Mean ECG-assesed Heart Rate	61.80 Beats/min Standard Deviation 10.06	—
Mean Heart Rate From Electrocardiogram Assessments at Specified Timepoints 26 weeks Mean ECG-assesed Heart Rate	64.50 Beats/min Standard Deviation 10.93	—
Mean Heart Rate From Electrocardiogram Assessments at Specified Timepoints 54 weeks Mean ECG-assesed Heart Rate	63.10 Beats/min Standard Deviation 12.43	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The differences in N across visits reflect the discontinuation of one subject due to pregnancy and the availability of determinations at each scheduled visit.

Evaluation of PR, QRS, QT , QTcB and QTcF intervals based on the analysis of electrocardiogram exams performed at baseline, 26 weeks and 54 weeks.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 26 weeks QTcB interval	407.30 msec Standard Deviation 34.80	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 54 weeks QTcB interval	420.20 msec Standard Deviation 41.39	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean Baseline QTcF interval	421.50 msec Standard Deviation 28.04	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 26 weeks QTcF interval	404.30 msec Standard Deviation 42.06	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 54 weeks QTcF interval	415.60 msec Standard Deviation 35.21	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean Baseline PR interval	130.30 msec Standard Deviation 45.71	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 26 weeks PR interval	119.2 msec Standard Deviation 36.72	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 54 weeks PR interval	127 msec Standard Deviation 37.98	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean Baseline QRS interval	79.5 msec Standard Deviation 10.05	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 26 weeks QRS interval	80.50 msec Standard Deviation 8.77	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 54 weeks QRS interval	85.50 msec Standard Deviation 16.40	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean Baseline QT interval	416.60 msec Standard Deviation 36.95	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 26 weeks QT interval	398.90 msec Standard Deviation 46.90	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean 54 weeks QT interval	411.10 msec Standard Deviation 37.79	—
Mean PR, QRS, QT, QTcB, and QTcF Intervals at Specified Timepoints Mean Baseline QTcB interval	417.20 msec Standard Deviation 22.05	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

Evaluation of cardiac function based on the analysis of bidimensional echocardiogram exams performed at baseline, 26 weeks and 54 weeks.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Left Ventricular Wall Thickness at Specified Timepoints Mean Baseline Left Ventricle wall thickness	9.04 mm Standard Deviation 2.27	—
Mean Left Ventricular Wall Thickness at Specified Timepoints Mean 26 weeks Left Ventricle wall thickness	8.38 mm Standard Deviation 2.47	—
Mean Left Ventricular Wall Thickness at Specified Timepoints Mean 54 weeks Left Ventricle wall thickness	9.65 mm Standard Deviation 2.29	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The differences in N across visits reflect the discontinuation of one subject due to pregnancy and the availability of determinations at each scheduled visit.

Evaluation of cardiac function based on the analysis of bidimensional echocardiogram exams performed at baseline, 26 weeks and 54 weeks.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Left Ventricular Mass Index at Specified Timepoints Mean 26 weeks Left Ventricular Mass Index	95.96 g/m² Standard Deviation 37.31	—
Mean Left Ventricular Mass Index at Specified Timepoints Mean 54 weeks Left Ventricular Mass Index	110.13 g/m² Standard Deviation 43.37	—
Mean Left Ventricular Mass Index at Specified Timepoints Mean Baseline Left Ventricular Mass Index	85.50 g/m² Standard Deviation 35.33	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®), 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: The difference in N at Week 54 is explained by the discontinuation of one subject due to pregnancy.

Evaluation of cardiac function based on the analysis of bidimensional echocardiogram exams performed at baseline, 26 weeks and 54 weeks.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Mean Left Ventricular Ejection Fraction at Specified Timepoints Mean Baseline Left Ventricle Ejection Fraction	65.16 percentage of ejection fraction Standard Deviation 6.21	—
Mean Left Ventricular Ejection Fraction at Specified Timepoints Mean 26 weeks Left Ventricle Ejection Fraction	64.42 percentage of ejection fraction Standard Deviation 7.27	—
Mean Left Ventricular Ejection Fraction at Specified Timepoints Mean 54 weeks Left Ventricle Ejection Fraction	63.28 percentage of ejection fraction Standard Deviation 11.22	—

SECONDARY outcome

Timeframe: Baseline (after 5 week lead-in period on Fabrazyme®),14 weeks, 26 weeks and 54 weeks (after the switch to AGA BETA BS).

Population: Only one patient was considered positive throughout the study for neutralizing ADA, as it shown \>50% neutralization from baseline to 54 weeks.

Count of participants whose serum samples showed a neutralization percentage of agalsidase beta activity greater than 50%, the predefined threshold indicating a positive result for neutralizing antibodies. Neutralizing antibody activity was evaluated using blood samples collected at Baseline, Week 14, Week 26, and Week 54. Participants with neutralization values exceeding the 50% cutoff were classified as positive for neutralizing antibodies at each timepoint.

Outcome measures

Outcome measures
Measure	Fabrazyme Then AGA BETA BS (Intention to Treat Population) n=19 Participants The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks	Fabrazyme Then AGA BETA BS (Per Protocol Population) Per Protocol set will include all participants who satisfactorily complete the study and comply with the requirements of the protocol. It is a subset of the ITT population without any major/Critical protocol deviations impacting the primary endpoint of the study.
Number of Participants With Positive Neutralizing Antibodies at Specified Timepoints Baseline	1 Participants	—
Number of Participants With Positive Neutralizing Antibodies at Specified Timepoints 14 weeks	1 Participants	—
Number of Participants With Positive Neutralizing Antibodies at Specified Timepoints 26 weeks	1 Participants	—
Number of Participants With Positive Neutralizing Antibodies at Specified Timepoints 54 weeks	1 Participants	—

Adverse Events

Lead-in Period (Fabrazyme)

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Treatment Period (AGA BETA BS)

Serious events: 5 serious events

Other events: 17 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Lead-in Period (Fabrazyme) n=20 participants at risk This is a single-arm study design where participants will serve as their own controls. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. Recombinant human alpha galactosidase A (agalsidase beta): All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks.	Treatment Period (AGA BETA BS) n=19 participants at risk After completing Lead-in period, all participants will switch treatment and receive AGA BETA BS for 54 weeks. Recombinant human alpha-galactosidase A (agalsidase beta): All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks.
Renal and urinary disorders Renal Atrophy	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.
Hepatobiliary disorders Cholelithiasis	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.
Nervous system disorders Ischaemic Stroke	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.
Cardiac disorders Atrial fibrillation	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.
General disorders Chest pain	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.
Infections and infestations Urinary tract infection	0.00% 0/20 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.	5.3% 1/19 • Number of events 1 • 13 months Adverse events were collected using multiple approaches to ensure completeness of safety data. Patients maintained diaries to record any adverse events occurring between visits. In addition, adverse events were systematically assessed at each scheduled study visit. Investigators also conducted follow-up telephone calls after each visit to capture any events that may have arisen in the interim.

Other adverse events

Additional Information

Nicolás Manuel Antognoni

Biosidus S.A.U.

Phone: +54 9 1140983909

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor requires investigators to submit any manuscripts or abstracts for review before public release to protect proprietary information. No specific embargo period is defined in the study documents. This review requirement constitutes a disclosure restriction applicable to investigators.
Publication restrictions are in place

Restriction type: OTHER